You have been redirected to this page from

genOway acquired Axenis to create the largest offer of preclinical models in the Immuno-oncology and Immuno-inflammation space.

Combining both platforms and knowhow creates the largest and most comprehensive offer for target validation and assessment of biologics and cell-based therapy in both Immuno-oncology (IO) and Immuno-inflammation (I&I). In particular, it addresses Immunotherapy and its need for relevant and translatable preclinical models for the assessment of novel therapeutic approaches.